Q3 2020 13F Holders as of 30 Sep 2020
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
6,235,531
-
Number of holders
-
103
-
Total 13F shares, excl. options
-
9,940,661
-
Shares change
-
+1,995,905
-
Total reported value, excl. options
-
$430,910,279
-
Value change
-
+$75,861,846
-
Put/Call ratio
-
27.91%
-
Number of buys
-
69
-
Number of sells
-
-40
-
Price
-
$43.36
Significant Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) as of Q3 2020
138 filings reported holding BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2020.
BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 per share (BTAI) has 103 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9,940,661 shares
.
Largest 10 shareholders include STATE STREET CORP (1,293,856 shares), Artemis Investment Management LLP (1,001,708 shares), VANGUARD GROUP INC (871,138 shares), BlackRock Inc. (810,132 shares), CITADEL ADVISORS LLC (749,621 shares), VICTORY CAPITAL MANAGEMENT INC (594,294 shares), ALLIANCEBERNSTEIN L.P. (590,285 shares), Logos Global Management LP (550,000 shares), Avidity Partners Management LP (538,000 shares), and MASSACHUSETTS FINANCIAL SERVICES CO /MA/ (290,117 shares).
This table shows the top 103 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.